BIIB : Summary for Biogen Inc. - Yahoo Finance

U.S. Markets open in 8 hrs 44 mins

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
287.63+0.73 (+0.25%)
At close: 4:00PM EST
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close286.90
Bid248.11 x 100
Ask289.20 x 1000
Day's Range285.22 - 289.43
52 Week Range223.02 - 333.65
Avg. Volume1,863,378
Market Cap62.11B
PE Ratio (TTM)16.99
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Did Biogen Inc. Shoot Itself in the Foot?
    Motley Fool16 hours ago

    Did Biogen Inc. Shoot Itself in the Foot?

    Biogen's list price for a new rare-disease drug makes it one of the world's most expensive. Was that a mistake?

  • American City Business Journalsyesterday

    ​Top pharma lobbyist casts Biogen as the anti-Shkreli during drug price Q&A

    The head of the pharmaceutical industry’s biggest Washington lobby group visited Boston on Tuesday as part of a public relations campaign aimed at countering criticism of high drug prices — and singled out Cambridge-based Biogen for praise. During a question-and-answer session with reporters Tuesday, Stephen Ubl, the head of the Pharmaceutical Research and Manufacturers of America, spoke out against what he called a handful of “bad actors” — companies that purchase off-patent medicines that lack generic competition and then significantly raise the price. As an example, he pointed to Biogen’s (BIIB) Spinraza, which in December became the first drug approved to treat spinal muscular atrophy, a leading genetic cause of death in infants.

  • Investopedia3 days ago

    Celgene MS Drug Reports Positive Phase 3 Data

    Celgene’s multiple sclerosis drug ozanimod beat rival Avonex in a Phase 3 study.